These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 9750499

  • 1. [PSATZ (prostate specific antigen adjusted for the transition zone volume)].
    Maeda H, Okubo K, Arai Y.
    Nihon Rinsho; 1998 Aug; 56(8):2016-20. PubMed ID: 9750499
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
    Furuya Y, Ohta S, Sato N, Kotake T, Sugano I, Nagao K, Masai M.
    Anticancer Res; 2001 Aug; 21(2B):1317-20. PubMed ID: 11396206
    [Abstract] [Full Text] [Related]

  • 3. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.
    Ann Clin Lab Sci; 2003 Aug; 33(3):320-3. PubMed ID: 12956448
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer.
    Moon DG, Cheon J, Kim JJ, Yoon DK, Koh SK.
    Int J Urol; 1999 Sep; 6(9):455-62. PubMed ID: 10510891
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [Abstract] [Full Text] [Related]

  • 7. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC, Ajzen SA.
    Int Braz J Urol; 2018 Jun; 44(4):709-716. PubMed ID: 29697929
    [Abstract] [Full Text] [Related]

  • 8. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
    Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y.
    Jpn J Clin Oncol; 2004 Oct; 34(10):602-7. PubMed ID: 15591458
    [Abstract] [Full Text] [Related]

  • 9. [Prostate cancer].
    Uchida K, Akaza H.
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [Abstract] [Full Text] [Related]

  • 10. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y, Okamura K, Takamura S, Okamoto N, Narishima M, Yoshino Y, Hattori R, Ono Y, Ohshima S, Nagasaka T.
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S, Suyama K, Matsumoto K, Kuwao S, Baba S.
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [Abstract] [Full Text] [Related]

  • 13. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 14. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N, Fujimoto K, Chihara Y, Torimoto M, Hirao Y, Konishi N, Saito I.
    Prostate Cancer Prostatic Dis; 2007 Oct; 10(3):274-8. PubMed ID: 17339878
    [Abstract] [Full Text] [Related]

  • 15. [Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml].
    Fujinami K, Miura T, Takizawa A, Osada Y, Kawakami S.
    Nihon Hinyokika Gakkai Zasshi; 2005 May; 96(4):475-9. PubMed ID: 15948407
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC, Hovey R, Carroll PR, Shinohara K.
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 19. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
    Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T.
    Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.